Selling a medical device in China requires registration with the National Medical Products Administration — the NMPA. The registration process is technical, time-consuming, and expensive, and it’s the primary barrier that foreign medical device manufacturers face when entering the China market. A company that starts the registration process without understanding the classification system, the clinical data requirements, and the timeline is going to be disappointed by how long it takes and how much it costs.
Here’s how the Chinese medical device registration system works and what a foreign manufacturer needs to do.
The Classification System
Chinese medical device regulation classifies devices into three classes based on risk. Class I devices are low-risk devices — surgical instruments, bandages, examination gloves — that are subject to a filing process rather than a full registration. The filing is a notification to the NMPA that the device is being marketed, and the processing time is fast — typically within a month.
Class II devices are medium-risk devices — ultrasound machines, X-ray equipment, infusion pumps — that require registration with the provincial-level medical products administration — the Guangdong MPA for a manufacturer in the GBA. The registration requires the manufacturer to submit technical documentation, to demonstrate that the device meets the applicable Chinese standards, and in some cases to submit clinical evaluation data. The processing time for a Class II registration is typically 12 to 18 months.
Class III devices are high-risk devices — implantable pacemakers, coronary stents, artificial joints — that require registration with the national NMPA. The registration requires comprehensive technical documentation, clinical trial data — or a clinical evaluation report based on clinical literature — and a quality management system audit of the manufacturer’s facility. The processing time for a Class III registration is typically 18 to 36 months, and the cost — including the registration fees, the testing fees, the clinical trial costs, and the professional fees — can exceed one million dollars.
A foreign manufacturer that’s entering the China market should determine the classification of its device before starting the registration process. The classification is based on the NMPA’s Medical Device Classification Catalog, and the classification may differ from the classification in the manufacturer’s home country. A device that’s Class II in the United States or the European Union may be Class III in China — or vice versa — and the classification determines the registration pathway and the cost and the timeline.
The Registration Process
The registration process starts with the appointment of a Chinese legal agent. A foreign manufacturer that doesn’t have a Chinese legal entity — a WFOE, a representative office, or a branch — must appoint a Chinese legal agent to act as the registration applicant. The legal agent is a Chinese company that’s registered with the NMPA and that’s authorized to submit the registration application on behalf of the foreign manufacturer. The legal agent is responsible for the accuracy and the completeness of the application, and the legal agent can be held liable for registration violations.
The legal agent requirement is a significant consideration for a foreign manufacturer that’s entering the China market. The legal agent controls the registration — the application is filed in the legal agent’s name — and the foreign manufacturer is dependent on the legal agent for the registration process and for the post-registration compliance. A foreign manufacturer that establishes a WFOE in China can be its own legal agent — the WFOE is the Chinese legal entity that submits the registration application — and the WFOE maintains control over the registration.
The registration application requires the technical documentation for the device — the device description, the design specifications, the manufacturing process, the quality control procedures — and the testing reports from Chinese-designated testing laboratories. The testing must be conducted by a laboratory that’s accredited by the NMPA, and the testing must demonstrate that the device meets the applicable Chinese standards — the GB standards, the YY standards, or the international standards recognized by the NMPA.
The clinical evaluation is required for Class II and Class III devices. The clinical evaluation can be a clinical trial — a prospective study conducted in Chinese hospitals with Chinese patients — or a clinical evaluation report — a review of the published clinical literature for the device or for an equivalent device. A clinical trial is the most rigorous form of clinical evaluation, and it’s required for devices that are novel, that have a high risk, or for which there’s insufficient clinical literature.
The clinical trial in China requires the approval of the NMPA — the clinical trial application must be approved before the trial can start — and the trial must be conducted at Chinese hospitals that are qualified to conduct clinical trials for the relevant device category. The clinical trial approval process takes six to twelve months, and the trial itself takes twelve to twenty-four months — longer for implantable devices that require long-term follow-up.
The quality management system audit is required for Class II and Class III devices. The NMPA or the provincial MPA conducts an on-site audit of the manufacturer’s facility — the manufacturing plant, the quality control laboratory, the sterilization facility — to confirm that the facility complies with the Chinese Good Manufacturing Practice requirements for medical devices. The audit is conducted by Chinese inspectors, and the audit report is in Chinese.
The Post-Registration Compliance
A registered medical device is subject to post-registration compliance requirements. The registration certificate is valid for five years, and the registration must be renewed before the expiry date. The renewal requires the manufacturer to submit updated technical documentation, updated clinical data, and evidence that the device has been manufactured in compliance with the quality management system requirements.
The manufacturer must report adverse events — incidents in which the device caused or contributed to a death or a serious injury, or in which the device malfunctioned and the malfunction would be likely to cause or contribute to a death or a serious injury. The adverse event reporting requirements in China are similar to the requirements in the United States and the European Union, and the manufacturer must have a system for receiving, investigating, and reporting adverse events from the Chinese market.
The manufacturer must also comply with the post-market surveillance requirements — the periodic safety update reports, the post-market clinical follow-up studies, and the device tracking requirements for implantable devices. The post-market surveillance requirements are more burdensome in China than in some other markets, and the manufacturer should budget for the cost of the post-market compliance.
The Localization Strategy
A foreign medical device manufacturer that’s entering the China market should consider a localization strategy — manufacturing the device in China rather than importing it. The localization strategy reduces the regulatory burden — a domestically manufactured device is subject to the same registration requirements as an imported device, but the post-registration compliance is simpler because the manufacturer is in China and can be inspected by the Chinese authorities more easily — and it reduces the cost — the import duties, the logistics costs, and the currency risk.
The localization strategy starts with the establishment of a WFOE in China — a manufacturing WFOE in an industrial zone in Shenzhen, Guangzhou, or one of the other GBA cities. The WFOE applies for the medical device manufacturing permit — a separate permit from the device registration — and the manufacturing facility is inspected by the NMPA or the provincial MPA. The manufacturing permit is renewed every five years, and the facility is subject to periodic unannounced inspections.
The localization strategy also aligns with the Chinese government’s policy of encouraging domestic manufacturing of medical devices. The government’s Made in China 2025 policy identifies medical devices as a priority sector, and the government offers incentives — tax benefits, R&D subsidies, procurement preferences — for domestically manufactured medical devices. A foreign manufacturer that localizes production in China positions itself to benefit from these policies.
The Distributor Model
A foreign manufacturer that doesn’t want to establish a WFOE in China can sell through a Chinese distributor. The distributor is the registration holder — the distributor applies for the device registration, holds the registration certificate, and is responsible for the regulatory compliance — and the foreign manufacturer supplies the device to the distributor under an OEM or a distribution agreement.
The distributor model transfers the regulatory burden to the distributor — the distributor handles the registration, the testing, the clinical evaluation, and the post-registration compliance — but it also transfers the control. The distributor controls the registration, and the foreign manufacturer is dependent on the distributor for access to the China market. A distributor who decides to terminate the distribution agreement — or who decides to source the device from a different manufacturer — leaves the foreign manufacturer without a China market presence.
The distributor model is appropriate for a foreign manufacturer that’s testing the China market and that’s not ready to commit to a WFOE. But the manufacturer should be aware that the distributor model creates a dependency on the distributor, and the manufacturer should have a plan for transitioning from the distributor model to a direct WFOE model when the market justifies the investment.
